“…To evaluate Scn8a -associated seizure protection directly in a model of epilepsy, we generated mice carrying the Scn1a -R1648H genetic epilepsy with febrile seizures plus (GEFS+) mutation (Makinson et al, 2016; Martin et al, 2010) and excitatory cell-specific deletion of Scn8a as outlined in Figure S4E. Deletion was found both to increase seizure latencies and to normalize survival (Figure S4F; Seizure latencies, GTCS, Scn8a fl/+ no-Cre , 443 ± 29 s, Scn8a fl/+ no-Cre Scn1a RH / + , 332 ± 15 s, Scn8a fl/+ Emx1 , 714 ± 50 s, Scn1a RH / + Scn8a fl/+ Emx1 , 612 ± 43 s, One-way ANOVA, Dunnett’s post hoc; Survival, Scn8a fl/+ no- Cre , 9/9, 100%, Scn8a fl/+ Emx1 , 7/7, 100%, Scn8a fl/+ no- Cre Scn1a RH/+ , 8/12, 66.7%, Scn1a RH / + Scn8a fl / + Emx1 , 8/8, 100%, Mantel-Cox test).…”